Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3)

被引：0

作者：

Ahmann, A. ^{[1
]}

Capehom, M. ^{[2
]}

Charpentier, G. ^{[3
]}

Dotta, E. ^{[4
]}

Henkel, E. ^{[5
]}

Lingvay, I. ^{[6
]}

Holst, A. Gaarsdal ^{[7
]}

Annett, M. ^{[8
]}

Aroda, V. ^{[9
]}

机构：

[1] Harold Schnitzer Diabet Hlth Ctr, Portland, OR USA

[2] Rotherham Inst Obes, Rotherham, S Yorkshire, England

[3] Ctr Hosp Sud Francilien, Corbeil Essonnes, France

[4] Univ Siena, Siena, Italy

[5] Tech Univ, Dresden, Germany

[6] UT Southwestern Med Ctr, Dallas, TX USA

[7] Novo Nordisk AS, Soborg, Denmark

[8] Novo Nordisk Inc, Plainsboro, NJ USA

[9] MedStar Hlth Res Inst, Hyattsville, MD USA

来源：

DIABETOLOGIA | 2016年 / 59卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

147

引用

页码：S76 / S76

页数：1

共 50 条

[1] Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3)
Ahmann, Andrew
Capehorn, Matthew
Charpentier, Guillaume
Dotta, Francesco
Henkel, Elena
Lingvay, Ildiko
Holst, Anders Gaarsdal
Annett, Miriam
Aroda, Vanita
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S51 - S51
[2] Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3)
Ahmann, Andrew J.
Capehorn, Matthew
Charpentier, Guillaume
Dotta, Francesco
Henkel, Elena
Lingvay, Ildiko
Holst, Anders Gaarsdal
Chang, Denise
Aroda, Vanita R.
[J]. DIABETES, 2016, 65 : A49 - A49
[3] Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with Type 2 diabetes (SUSTAIN 2)
Ahren, B.
Comas, L. M.
Kumar, H.
Sargin, M.
Karsbol, J. D.
Jacobsen, S. H.
Chow, F.
[J]. DIABETIC MEDICINE, 2017, 34 : 145 - 145
[4] Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with type 2 diabetes (SUSTAIN 2)
Ahren, B.
Comas, L. Masmiquel
Kumar, H.
Sargin, M.
Karsbol, J. Derving
Jacobsen, S. Hald
Chow, F.
[J]. DIABETOLOGIA, 2016, 59 : S365 - S365
[5] Efficacy and Safety of Once-Weekly Semaglutide vs. Sitagliptin as Add-on to Metformin and/or Thiazolidinediones after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 2)
Ahren, Bo
Comas, Luis Masmiquel
Kumar, Harish
Sargin, Mehmet
Karsbol, Julie Derving
Jacobsen, Sanja Hald
Chow, Francis
[J]. DIABETES, 2016, 65 : A48 - A48
[6] Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in subjects with Type 2 diabetes (SUSTAIN 1)
Sorli, C.
Harashima, S-I
Tsoukas, G.
Unger, J.
Karsbol, J. D.
Bain, S.
[J]. DIABETIC MEDICINE, 2017, 34 : 145 - 145
[7] Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Ahmann, Andrew J.
Capehorn, Matthew
Charpentier, Guillaume
Dotta, Francesco
Henkel, Elena
Lingvay, Ildiko
Holst, Anders G.
Annett, Miriam P.
Aroda, Vanita R.
[J]. DIABETES CARE, 2018, 41 (02) : 258 - 266
[8] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)
Harashima, Shin-ichi
Sorli, Christopher
Tsoukas, George
Unger, Jeffrey
Karsbol, Julie Derving
Hansen, Thomas
Bain, Stephen
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S121 - S121
[9] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)
Sorli, C.
Harashima, S. -I.
Tsoukas, G.
Unger, J.
Karsbol, J. Derving
Hansen, T.
Bain, S.
[J]. DIABETOLOGIA, 2016, 59 : S364 - S364
[10] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
DeVries, J. H.
Bain, S. C.
Cariou, B.
Rose, L.
Axelsen, M.
Rowe, E.
Aroda, V. R.
[J]. DIABETOLOGIA, 2016, 59 : S76 - S77

← 1 2 3 4 5 →